FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896638654> ?p ?o ?g. }

• W2896638654 endingPage "455" @default.
• W2896638654 startingPage "455" @default.
• W2896638654 abstract "Background As oral surgical procedures like implantations and augmentative procedures per se can lead to severe haemorrhagia, in particular patients on anticoagulants require appropriate management. The “Graz Considerations for Compromised Coagulation” (GCCC) have been introduced to international field specialists in Vienna, Austria, in 2005 and takes most of invasive dental treatments into account. The recent update of the GCCC has forwarded the optimal peri-procedural haemostatic strategy by. Material and Methods To identify relevant studies a comprehensive and systematic literature research in high-yield journals and the electronic database PubMed was conducted. The broad spectrum of information about perioperative hemostatic strategies was examined using the following search terms – “oral surgery“, “implant surgery“, “DOAC” and the agents’ proper names. In light of relevant international publications we evaluate our current findings in an ongoing study at our department. Results Characteristics of included studies are compared with the pertinent data of our study and listed in tabular form. Seven published papers were included in our critical evaluation. Two cohort studies tested continuation versus discontinuation of DOAC (Rivaroxaban, Xarelto®) for certain procedures in oral surgery. In one study group no significance for bleeding events of dental implantations was detected in comparison to normal population while another trial showed significance. Three work groups presented their protocols of temporary discontinuation of Dabigatran (Pradaxa®). In strict accordance with their periprocedural strategies the authors observed no significant difference of bleeding events. One working group provides detailed recommendations in a review, but had not assessed them in a clinical trial. An Australian study team recommends both continuation and discontinuation of Dabigatran according to the individual bleeding risk, nevertheless their results may not be represent. Conclusions and Clinical Implications Hematologists advise a minimum time-interval of last dose to intervention. In accordance with our clinical study results we found that continuation of DOAC therapy is advisable for simple implantation without increased risk of local haemorrhage. The DOACs’ temporary suspension may, however, show fewer bleeding events in procedures such as complex implantation. As limited data regarding bleeding in implant patients under DOAC therapy is available further studies are needed to determine." @default.
• W2896638654 created "2018-10-26" @default.
• W2896638654 creator A5053633813 @default.
• W2896638654 date "2018-10-01" @default.
• W2896638654 modified "2023-09-25" @default.
• W2896638654 title "Direct Oral Anticoagulants (DOAC) in oral implant surgery - a metaanalysis" @default.
• W2896638654 doi "https://doi.org/10.1111/clr.340_13358" @default.
• W2896638654 hasPublicationYear "2018" @default.
• W2896638654 type Work @default.
• W2896638654 sameAs 2896638654 @default.
• W2896638654 citedByCount "0" @default.
• W2896638654 crossrefType "journal-article" @default.
• W2896638654 hasAuthorship W2896638654A5053633813 @default.
• W2896638654 hasBestOaLocation W28966386541 @default.
• W2896638654 hasConcept C126322002 @default.
• W2896638654 hasConcept C141071460 @default.
• W2896638654 hasConcept C15744967 @default.
• W2896638654 hasConcept C180747234 @default.
• W2896638654 hasConcept C2776301958 @default.
• W2896638654 hasConcept C2778661090 @default.
• W2896638654 hasConcept C2778715236 @default.
• W2896638654 hasConcept C2778810321 @default.
• W2896638654 hasConcept C2779161974 @default.
• W2896638654 hasConcept C2779356329 @default.
• W2896638654 hasConcept C2908647359 @default.
• W2896638654 hasConcept C31174226 @default.
• W2896638654 hasConcept C535046627 @default.
• W2896638654 hasConcept C71924100 @default.
• W2896638654 hasConcept C99454951 @default.
• W2896638654 hasConceptScore W2896638654C126322002 @default.
• W2896638654 hasConceptScore W2896638654C141071460 @default.
• W2896638654 hasConceptScore W2896638654C15744967 @default.
• W2896638654 hasConceptScore W2896638654C180747234 @default.
• W2896638654 hasConceptScore W2896638654C2776301958 @default.
• W2896638654 hasConceptScore W2896638654C2778661090 @default.
• W2896638654 hasConceptScore W2896638654C2778715236 @default.
• W2896638654 hasConceptScore W2896638654C2778810321 @default.
• W2896638654 hasConceptScore W2896638654C2779161974 @default.
• W2896638654 hasConceptScore W2896638654C2779356329 @default.
• W2896638654 hasConceptScore W2896638654C2908647359 @default.
• W2896638654 hasConceptScore W2896638654C31174226 @default.
• W2896638654 hasConceptScore W2896638654C535046627 @default.
• W2896638654 hasConceptScore W2896638654C71924100 @default.
• W2896638654 hasConceptScore W2896638654C99454951 @default.
• W2896638654 hasLocation W28966386541 @default.
• W2896638654 hasOpenAccess W2896638654 @default.
• W2896638654 hasPrimaryLocation W28966386541 @default.
• W2896638654 hasRelatedWork W1637794943 @default.
• W2896638654 hasRelatedWork W2016226059 @default.
• W2896638654 hasRelatedWork W2220556496 @default.
• W2896638654 hasRelatedWork W2342107936 @default.
• W2896638654 hasRelatedWork W2603244127 @default.
• W2896638654 hasRelatedWork W2750836949 @default.
• W2896638654 hasRelatedWork W2802930797 @default.
• W2896638654 hasRelatedWork W2967596543 @default.
• W2896638654 hasRelatedWork W3118338237 @default.
• W2896638654 hasRelatedWork W4228999874 @default.
• W2896638654 hasVolume "29" @default.
• W2896638654 isParatext "false" @default.
• W2896638654 isRetracted "false" @default.
• W2896638654 magId "2896638654" @default.
• W2896638654 workType "article" @default.